NCT05570305 - Zibotentan and Dapagliflozin in Patients With Type 2 Diabetes and Elevated Albuminuria | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

October 6, 2022

Primary Completion Date

March 5, 2025

Study Completion Date

March 5, 2025

Conditions

Chronic Kidney Diseases

Interventions

DRUG

Zibotentan

Zibotentan 1.5 mg once per day as a hard capsule.

DRUG

Dapagliflozin

Dapagliflozin 10 mg once per day as a tablet.

DRUG

Placebo

Matching placebo.

DRUG

Dapagliflozin and Zibotentan

Dapagliflozin 10 mg once per day as a tablet in combination with zibotentan 1.5 mg once per day as a hard capsule.

Trial Locations (7)

Anschutz Medical Campus, Aurora

Toronto General Hospital, Toronto

Montreal Clinical Research Institute, Montreal

Steno Diabetes Center, Copenhagen

Amsterdam Universitair Academisch Centrum, Amsterdam

University Medical Center Groningen, Groningen

Center for Cardiovascular Science, Edinburgh